Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05652855




Registration number
NCT05652855
Ethics application status
Date submitted
30/11/2022
Date registered
15/12/2022
Date last updated
9/01/2023

Titles & IDs
Public title
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
Scientific title
Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors
Secondary ID [1] 0 0
MHB088C-CP001EN
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced or Metastatic Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MHB088C for Injection

Experimental: MHB088C administered - MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W).


Treatment: Drugs: MHB088C for Injection
MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Evaluate the incidence of adverse events (AEs)
Timepoint [1] 0 0
through study completion, an average of 1 year
Primary outcome [2] 0 0
Evaluate the incidence of dose-limiting toxicities (DLTs)
Timepoint [2] 0 0
through study completion, an average of 1 year
Primary outcome [3] 0 0
Determine the recommended Phase 2 dose (RP2D) of MHB088C
Timepoint [3] 0 0
through study completion, an average of 1 year
Secondary outcome [1] 0 0
Pharmacokinetics (PK) parameter: Maximum concentration (Cmax)
Timepoint [1] 0 0
Within 5 cycles (each cycle is 28 days)
Secondary outcome [2] 0 0
PK parameter: Time to maximum concentration (Tmax)
Timepoint [2] 0 0
Within 5 cycles (each cycle is 28 days)
Secondary outcome [3] 0 0
PK parameter: Area under the concentration-time curve (AUC)
Timepoint [3] 0 0
Within 5 cycles (each cycle is 28 days)
Secondary outcome [4] 0 0
PK parameter: Trough concentration (Ctrough)
Timepoint [4] 0 0
Within 5 cycles (each cycle is 28 days)
Secondary outcome [5] 0 0
PK parameter: Terminal or apparent terminal half-life (t1/2)
Timepoint [5] 0 0
Within 5 cycles (each cycle is 28 days)
Secondary outcome [6] 0 0
PK parameter: Systemic clearance (CL)
Timepoint [6] 0 0
Within 5 cycles (each cycle is 28 days)
Secondary outcome [7] 0 0
Immunogenicity Assessment
Timepoint [7] 0 0
Within 5 cycles (each cycle is 28 days)
Secondary outcome [8] 0 0
Objective Response Rate (ORR)
Timepoint [8] 0 0
through study completion, an average of 1 year
Secondary outcome [9] 0 0
Duration of Response (DOR)
Timepoint [9] 0 0
through study completion, an average of 1 year
Secondary outcome [10] 0 0
Disease Control Rate (DCR)
Timepoint [10] 0 0
through study completion, an average of 1 year
Secondary outcome [11] 0 0
Progression Free Survival (PFS)
Timepoint [11] 0 0
through study completion, an average of 1 year

Eligibility
Key inclusion criteria
-

Participants enrolled must meet all of the following criteria:

General conditions

1. Participants voluntarily agree to participate in the study and sign the Informed
Consent Form.

2. Aged =18years, without gender limitation.

3. Has an Eastern Cooperative Oncology Group Performance score (ECOG) 0 ~ 1.

4. Has a life expectancy of = 3 months.

5. Eligible participants of childbearing potential (males and females) must agree to take
highly reliable contraceptive measures (hormone or barrier method, or absolute
abstinence, etc.) with their partners during the study and within at least 90 days
after the last dose and agree not to retrieve, freeze or donate sperm or ova from
screening to at least 3 months after the last dose of investigational drug; female
participants of childbearing potential must have a negative results of blood pregnancy
test within 7 days before the first dose of investigational drug, and must be
non-lactating.

6. Understand study requirements, willing and able to comply with study and follow-up
procedures.

Neoplasm-related criteria

7. Part one: Histologically or cytologically confirmed unresectable advanced or
metastatic malignant solid tumors, that is progressed or intolerant with standard of
care (SOC), or for which no SOC regimens are available;

8. Part two: Histologically or cytologically confirmed unresectable advanced or
metastatic malignant solid tumors, that is relapsed or progressed following systemic
treatment or no standard of care is available, including but not limited to the
following types: non-small cell lung cancer (NSCLC); small cell lung cancer (SCLC);
esophageal squamous cell carcinoma (ESCC); castration-resistant prostate cancer
(CRPC); melanoma (MEL); colorectal cancer (CRC); pancreatic ductal adenocarcinoma
(PDAC); head and neck squamous cell carcinoma (HNSCC); hepatocellular carcinoma (HCC);
ovarian cancer (OC); endometrial cancer (EC); thyroid cancer (TC); and sarcoma (SARC).

1. Additional inclusion criteria for participants with NSCLC:

Histologically or cytologically documented unresectable advanced or metastatic
NSCLC and previous progressed during or after systematic treatment with
platinum-contained doublet regimens chemotherapy and immune-checkpoint inhibitors
(ICIs); refractory, intolerant or not suitable to the target therapy as per
investigator discretion for participants with driver gene mutation.

2. Additional inclusion criteria for participants with SCLC:

Histologically or cytologically documented unresectable advanced or metastatic
SCLC and previous progressed during or after =1 lines of systematic treatment
with platinum-based, doublet regimens chemotherapy and ICIs.

3. Additional inclusion criteria for participants with ESCC:

Histologically or cytologically documented unresectable advanced or metastatic
ESCC previous progressed during or after=1 line platinum-based of systemic
treatment.

4. Additional inclusion criteria for participants with CRPC:

Histologically or cytologically documented CRPC without neuroendocrine
differentiation or small cell elements; Underwent surgical or medical castration,
with testosterone levels below 50 ng/dL; Objective progression as determined by
radiographic after androgen deprivation therapy; Relapsed or progressed during or
after at least one of the following medicines: abiraterone, enzalutamide,
apalutamide, or darolutamide; Relapsed or progressed during or after= 1 line of
docetaxel/mitoxantrone-based cytotoxic chemotherapy regimens for metastatic CRPC;
With at least 1 documented lesion confirmed by either a bone scan or a CT/MRI
scan.

5. Additional inclusion criteria for participants with MEL:

Histologically or cytologically documented unresectable advanced or metastatic
MEL and previous progressed during or after =1 line of systemic therapy including
ICIs

6. Additional inclusion criteria for participants with CRC:

Histologically or cytologically documented unresectable advanced or metastatic
CRC and previous progressed during or after systematic chemotherapy containing
oxaliplatin, irinotecan, fluorouracil and immunotherapy (for participants with
MSI-H/dMMR).

7. Additional inclusion criteria for participants with PDAC:

Histologically or cytologically documented unresectable advanced or metastatic
PDAC and previous progressed during or after = 1 line of systemic therapy in
neoadjuvant, adjuvant, locally advanced or metastatic setting.

8. Additional inclusion criteria for participants with HNSCC:

Histologically or cytologically documented unresectable advanced or metastatic
HNSCC and previous progressed during or after = 1 line of systemic therapy,
including platinum-based chemotherapy and ICIs (combined or sequential therapy).

9. Additional inclusion criteria for participants with HCC:

Histologically or cytologically documented unresectable advanced or metastatic
HCC and previously progressed during or after = 1 line of systemic therapy,
including anti-vascular therapy and/or ICI therapy.

10. Additional inclusion criteria for participants with OC:

Histologically or cytologically documented unresectable advanced or metastatic OC
including less-common histology per National Comprehensive Cancer Network (NCCN)
of epithelial ovarian cancer as well as fallopian tube cancer and primary
peritoneal cancer and have relapsed or progressed during or after = 1 line of
platinum-based systemic chemotherapy treatment.

11. Additional inclusion criteria for participants with EC:

Histologically or cytologically documented unresectable advanced or metastatic EC
and recurrence after radical therapy, and previously treated and progressed
during or after = 1 line of standard systemic therapy.

12. Additional inclusion criteria for participants with TC:

Histologically or cytologically documented unresectable advanced or metastatic TC
and previous progressed during or after = 1 line of systemic therapy including
platinum-based chemotherapy or targeted therapy.

13. Additional inclusion criteria for participants with SARC:

Histologically or cytologically documented unresectable advanced or metastatic SARC
and previous progressed during or after = 1 prior line of systemic therapy including
doxorubicin-based chemotherapy.

9. Agree to provide the pre-existing diagnostic tumor samples for retrospective testing
of target expression and other biomarkers (participants who agree but are unable to
provide pre-existing tumor sample may also be enrolled). There is no minimum target
expression level required for inclusion.

10. Has at least one measurable tumor lesion as per RECIST v1.1(generally, previously
irradiated areas or locoregionally treated sites will not be considered as measurable
lesions, unless these lesions have clearly progressed or still exist three months
after radiotherapy); for participants with CRPC, evaluable lesions as defined by PCWG3
criteria or at least one measurable soft tissue tumor lesion as per RECIST v1.1 are
required.

Adequate bone marrow reserve and organ functions:

11. Adequate bone marrow reserve (without transfusion or colony-stimulating factor or
equivalent within7 days before the screening period testing); Absolute neutrophil
count (ANC) = 1.5 × 10^9/L; Platelet count = 100 × 10^9/L; Hemoglobin = 9.0 g/dL.

12. Adequate hepatic function (with reference to normal values specified by the clinical
study site):

Total bilirubin (TBIL) = 1.5 × upper limit of normal (ULN); TBIL = 2 × ULN if
Gilbert's syndrome is present; TBIL = 3.0 × ULN is permitted if direct bilirubin
(DBIL) suggests extrahepatic obstruction.

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) shall be = 3 × ULN
with non-hepatic tumors and without hepatic metastasis; AST and ALT shall be = 5.0 ×
ULN with hepatic tumors or hepatic metastasis;

13. Adequate renal function (with reference to normal values specified by the clinical
study site):

Creatinine (Cr) = 1.5 × ULN; when Cr > 1.5 × ULN, only participants with creatinine
clearance (Ccr) = 50 mL/min can be enrolled (using Cockcroft-Gault formula);

14. Adequate coagulation function:

Activated partial thromboplastin time (APTT) = 1.5 × ULN, and international normalized
ratio (INR) = 1.5 × ULN.

15. Adequate cardiac function:

Left ventricular ejection fraction (LVEF) = 50% by echocardiogram within 28 days before
enrollment; New York Heart Association (NYHA) Class < grade 3.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
-

Participants will be not enrolled if they meet any of the following exclusion criteria:

Neoplasm-related criteria:

1. Has more than 2 primary malignancies (except curatively treated non-melanoma skin
cancer, in situ disease, and other curatively malignancies have considered cured)
within 5 years before signing of Informed Consent Form.

2. Has received chemotherapy within 3 weeks, or have received anti-tumor treatment
including radiation therapy, biologic therapy, endocrine therapy, immunotherapy, etc.
within 4 weeks before the first dose of investigational product; or participants with
the following conditions:

Medication of nitrosourea or mitomycin C within 6 weeks before the first dose of
investigational drug; Medication of oral fluoropyrimidines and small molecule targeted
agents within 5 half-lives before the first dose of investigational drug; Medication
of traditional Chinese medicine with anti-tumor indication within 2 weeks before the
first dose of investigational drug.

3. Medication of other unmarketed investigational drugs or therapies within 4 weeks
before the first dose of investigational drug.

4. Presence of brain metastases and/or leptomeningeal carcinomatosis. Participants
previously treated for brain metastases may be considered to be enrolled in this
study, provided they have been in stable condition for at least 1 month, have no
progression confirmed by radiographic examination within 4 weeks before the first dose
of study treatment, all neurological symptoms have stabled, there is no evidence of
new or enlarging brain metastases, and radiation or surgical therapy is discontinued
for at least 28 days before the first dose of study treatment and steroid therapy at
the dose of =10 mg/day or similar drugs at equivalent dose within 14 days before the
first dose and during the study. This exception does not include carcinomatous
meningitis, which should be excluded regardless of clinical stability.

5. Has previously received same target therapy.

6. Has adverse reactions from previous anti-tumor treatment that have not recovered to =
CTCAE 5.0 Grade 1 (except for toxicities without safety risks as determined by the
investigator, such as alopecia, hypothyroidism stably managed by hormone replacement
therapy, etc.).

General conditions:

7. Has underwent major organ surgery (excluding biopsy) or significant trauma within 4
weeks before the first dose of investigational drug or requiring elective surgery
during the study.

8. Has vaccinated with attenuated live vaccines (except for SARS-CoV-2 vaccination)
within 4 weeks before the first dose of investigational drug.

9. Has mucosal or internal bleeding for non-traumatic reason within 4 weeks before the
first dose of investigational drug.

10. Has received treatment with systemic corticosteroids (prednisone at >10 mg/day, or
similar drugs at equivalent dose) or other immunosuppressive agents within 14 days
before the first dose of investigational drug, with the following exceptions:

Treatment with topical, ocular, intra-articular, intranasal, and inhaled
corticosteroids; Short-term use of glucocorticoids for prophylaxis (e.g., prevention
of contrast media allergy).

11. Has pulmonary disease that severely impact pulmonary function, including, but not
limited to, potential pulmonary disease, any autoimmune diseases, connective tissue
diseases, or inflammatory diseases involving the pulmonary, or pneumonectomy.

12. Has history of non-infectious interstitial lung disease (ILD)/pneumonitis that
required steroids, or current ILD/pneumonia, or suspected ILD/pneumonia that cannot be
excluded by imaging examination at screening.

13. Has active pulmonary tuberculosis.

14. Has active infection requiring systemic therapy.

15. Has positive results in virus serology tests (participants receiving antiviral
prophylaxis other than interferon are allowed to be enrolled):

Positive result of HIV antibody; Or, positive for both HBsAg and HBV-DNA (i.e., HBV
DNA =LLOD); Or, positive for HCV Ab (except HCV-RNA < LLOD).

16. Has positive result for covid-19 nucleic acid test.

17. Medical history of serious cardiovascular and cerebrovascular diseases, including but
not limited to:

Severe arrhythmia or conduction abnormalities, such as ventricular arrhythmia
requiring clinical intervention, or atrioventricular block ?~? degree;
Fridericia-corrected QT interval (QTcF) prolongation to >450 milisecond (ms) for males
and > 470 ms for females; Acute coronary syndrome, aortic dissection, stroke or
transient ischemic attack (TIA) within 6 months before the first dose; New myocardial
infarction or unstable angina within 6 months before the first dost; Clinically
uncontrolled hypertension;

18. Has clinically uncontrolled effusion in third spacing, deemed as inappropriate for
enrollment by the investigator.

19. Hypersensitivity or delayed hypersensitivity to certain components or analogues of the
investigational drug.

20. Has drug abuse or any other medical conditions, such as clinically significant
psychological conditions that may interfere with study participation or the results of
the clinical study as per investigator discretion.

21. Has alcohol or drug dependence.

22. Females who are pregnant or breastfeeding, or males/females who plan to father a
child/get pregnant.

23. Poor compliance as per investigator discretion, has history of other serious systemic
diseases, or unsuitable to participate this clinical study for some reasons.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
23/01/2023
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/07/2026
Actual
Sample size
Target
48
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Pindara Private Hospital - Gold Coast
Recruitment hospital [2] 0 0
Southern Oncology Clinical Research Unit - Adelaide
Recruitment hospital [3] 0 0
Cabrini Health - Melbourne
Recruitment postcode(s) [1] 0 0
4217 - Gold Coast
Recruitment postcode(s) [2] 0 0
5042 - Adelaide
Recruitment postcode(s) [3] 0 0
3144 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Minghui Pharmaceutical Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB088C in
participants with advanced or metastatic solid tumors.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05652855
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Contact for Clinical Trial Information Minghui Pharmaceutical
Address 0 0
Country 0 0
Phone 0 0
086-02160898367
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05652855